New York Life Investment Management LLC Makes New $948,000 Investment in Elanco Animal Health Incorporated $ELAN

New York Life Investment Management LLC bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 41,903 shares of the company’s stock, valued at approximately $948,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Independent Advisor Alliance increased its stake in shares of Elanco Animal Health by 1.0% in the fourth quarter. Independent Advisor Alliance now owns 99,028 shares of the company’s stock valued at $2,241,000 after buying an additional 1,003 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Elanco Animal Health by 48.3% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 117,173 shares of the company’s stock valued at $2,652,000 after buying an additional 38,150 shares in the last quarter. Swiss Life Asset Management Ltd increased its stake in shares of Elanco Animal Health by 55.7% in the fourth quarter. Swiss Life Asset Management Ltd now owns 35,491 shares of the company’s stock valued at $803,000 after buying an additional 12,702 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at $219,000. Finally, Ethic Inc. increased its stake in shares of Elanco Animal Health by 13.6% in the fourth quarter. Ethic Inc. now owns 63,914 shares of the company’s stock valued at $1,446,000 after buying an additional 7,660 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Price Performance

Shares of ELAN opened at $19.78 on Wednesday. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 1 year low of $12.40 and a 1 year high of $27.72. The stock has a market cap of $9.88 billion, a P/E ratio of -39.55, a price-to-earnings-growth ratio of 2.14 and a beta of 1.69. The stock’s 50-day moving average price is $23.16 and its two-hundred day moving average price is $23.31.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter last year, the business earned $0.37 earnings per share. The company’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Insider Transactions at Elanco Animal Health

In related news, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. KeyCorp raised their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Leerink Partners raised their target price on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. raised their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus price target of $28.20.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.